Targeting Prefrontal Cortex Dysfunction in Pain
The Journal of Pharmacology and Experimental Therapeutics · 2024-06 · 389 (3) · 268-276
DOI: 10.1124/jpet.123.002046 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2024-06. Verfasst von Kai Kummer und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Physiology, Medical University of Innsbruck, Innsbruck, Austria (K.K.); Department of Pharmacology and Toxicology (P.L.S.), Medical Neur…. Hauptthemen laut MEDLINE: Prefrontal Cortex. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 181 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS.
Abstract (Originalsprache)
The prefrontal cortex (PFC) has justifiably become a significant focus of chronic pain research. Collectively, decades of rodent and human research have provided strong rationale for studying the dysfunction of the PFC as a contributing factor in the development and persistence of chronic pain and as a key supraspinal mechanism for pain-induced comorbidities such as anxiety, depression, and cognitive decline. Chronic pain alters the structure, chemistry, and connectivity of PFC in both humans and rodents. In this review, we broadly summarize the complexities of reported changes within both rodent and human PFC caused by pain and offer insight into potential pharmacological and nonpharmacological approaches for targeting PFC to treat chronic pain and pain-associated comorbidities. SIGNIFICANCE STATEMENT: Chronic pain is a significant unresolved medical problem causing detrimental changes to physiological, psychological, and behavioral aspects of life. Drawbacks of currently approved pain therapeutics include incomplete efficacy and potential for abuse producing a critical need for novel approaches to treat pain and comorbid disorders. This review provides insight into how manipulation of prefrontal cortex circuits could address this unmet need of more efficacious and safer pain therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Institute of Physiology, Medical University of Innsbruck, Innsbruck, Austria (K.K.); Department of Pharmacology and Toxicology (P.L.S.), Medical Neurosciences Graduate Program (P.L.S.), and Stark Neurosciences Research…
Förderung
- NINDS NIH HHS
Zitieren
APA
Kummer, K., & Sheets, P. L. (2024). Targeting Prefrontal Cortex Dysfunction in Pain. The Journal of Pharmacology and Experimental Therapeutics, 389(3), 268-276. https://doi.org/10.1124/jpet.123.002046
Vancouver
Kummer K, Sheets PL. Targeting Prefrontal Cortex Dysfunction in Pain. The Journal of Pharmacology and Experimental Therapeutics. 2024;389(3):268-276. doi:10.1124/jpet.123.002046
BibTeX
@article{Kummer2024,
author = {Kummer, Kai and Sheets, Patrick L},
title = {Targeting Prefrontal Cortex Dysfunction in Pain},
journal = {The Journal of Pharmacology and Experimental Therapeutics},
year = {2024},
volume = {389},
number = {3},
pages = {268--276},
doi = {10.1124/jpet.123.002046}
}
EUVIMED